Knoll Capital Management Portfolio Update: June 2026
Knoll Capital Management's portfolio, valued at approximately $286 million as of June 30, 2026, maintained its focus on healthcare stocks while showing slight adjustments in specific holdings.
Knoll Capital Management, Llc reported a portfolio value of $286,242,990 as of June 30, 2026.
The portfolio maintained a significant focus on the Basic Materials sector, primarily through holdings in gold-related assets like Knoll Capital Management, Llc and Royal Gold Inc. (RGLD).
Several healthcare holdings saw notable changes:
- Ocular Therapeutix Inc. (OCUL) experienced a substantial increase, with shares rising by 91.61% to 1,150,400 units, representing a significant position increase.
- Elicio Therapeutics Inc. (ELTX) also saw a large increase, with shares rising by 92.1%.
- Nuvation Bio Inc. (NUVB) increased its stake by 6.67%.
- Abivax SA Spons. (ABVX) increased its stake by 100%.
Other holdings remained unchanged from the previous period, including Sprott physical gold Trust (PHYS) and Aldeyra Therapeutics Inc. (ALDX).
The overall portfolio allocation shows:
- Healthcare: 31.39%
- Basic Materials: 49.87%
- Unknown: 12.73%
- Industrials: 4.75%
- Consumer Defensive: 1.26%
The portfolio indicates a moderate concentration in its top holdings, with the top five positions accounting for 14.73% of the total value.